If you are one of those who pop painkillers all too often, then you might be raising your risk of heart attack and heart ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size, according to a new study led by UCL ...

Affinia Therapeutics Inc. has nominated AFTX-201 as a development candidate for the treatment of BAG3 dilated cardiomyopathy. The gene therapy, using Affinia’s cardiotropic capsid, is given as a ...

So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment. In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, ...

More than one million people in the UK have heart failure, with 200,000 new diagnoses every year. It can be easy to miss in ...

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

The FDA has issued a CRL to Lexicon regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for T1D and CKD.

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic ...